Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D. et al, (2011), Clin Cancer Res, 17, 3420 - 3430
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N. et al, (2011), Cancer Res, 71, 3317 - 3327
The biological and therapeutic relevance of mRNA translation in cancer.
Blagden SP. and Willis AE., (2011), Nat Rev Clin Oncol, 8, 280 - 291
Molecular targets in ovarian cancer
Agarwal R. and Blagden S., (2011), Cancer and Chemotherapy Reviews, 6, 37 - 44
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer
Gungor H. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, 12 - 13
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.
Gungor H. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration.
Burrows C. et al, (2010), Nucleic Acids Res, 38, 5542 - 5553
Drosophila Larp associates with poly(A)-binding protein and is required for male fertility and syncytial embryo development.
Blagden SP. et al, (2009), Dev Biol, 334, 186 - 197
Promising molecular targets in ovarian cancer.
Blagden S. and Gabra H., (2009), Curr Opin Oncol, 21, 412 - 419
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Scott EN. et al, (2009), Cancer Chemother Pharmacol, 64, 425 - 429
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors.
Olmos D. et al, (2009), J Clin Oncol, 27
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.
Sharma R. et al, (2009), Br J Cancer, 100, 707 - 712
A phase i dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Scott EN. et al, (2009), Cancer Chemotherapy and Pharmacology, 64, 425 - 429
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors
Olmos D. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27
Future directions in the management of epithelial ovarian cancer.
Blagden S. and Gabra H., (2008), Future Oncol, 4, 403 - 411
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP. et al, (2008), Br J Cancer, 98, 894 - 899
A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors
Blagden S. et al, (2008), EJC SUPPLEMENTS, 6, 135 - 136
Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer
Blagden S. et al, (2008), EJC SUPPLEMENTS, 6, 135 - 135
Patterns of relapse in patients treated with surgery followed by platinum based chemotherapy for advanced epithelial ovarian cancer
Tuthill MH. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Attard G. et al, (2007), Br J Cancer, 97, 1338 - 1343